DioTree

Dio-Tree is a biotechnology company developing a first-in-class therapeutic approach for ovarian cancer by targeting the enzyme DIO3 within tumor cells. DIO3 regulates intracellular thyroid hormone activity, and its dysregulation supports cancer cell proliferation and survival. By modulating thyroid hormone signaling directly in tumor cells, Dio-Tree aims to inhibit tumor growth through a novel mechanism distinct from current therapies. The company’s lead program is in the preclinical stage, demonstrating strong efficacy in multiple in vivo ovarian cancer models, including clinically relevant orthotopic systems, alongside a favorable safety profile. Dio-Tree is advancing toward first-in-human clinical trials, supported by a multidisciplinary team and leading scientific advisors. With potential applications across multiple solid tumors, Dio-Tree is positioned to pioneer a new class of cancer therapies based on intracellular metabolic regulation.